<DOC>
	<DOCNO>NCT02654509</DOCNO>
	<brief_summary>This study conduct collect safety immunogenicity data EEE vaccine .</brief_summary>
	<brief_title>Safety Immunogenicity Study Eastern Equine Encephalitis ( EEE ) Vaccine , Inactivated , Dried , TSI-GSD 104 , Lot 2-1-89 , Healthy Adult Subjects Risk Exposure Eastern Equine Encephalitis Virus</brief_title>
	<detailed_description />
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalomyelitis , Equine</mesh_term>
	<mesh_term>Encephalomyelitis , Eastern Equine</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Be 18 65 year old time consent . 2 . Have EEE virus plaque reduction neutralization 80 % titer ( PRNT80 ) &lt; 1:20 primary series . 3 . Have EEE virus PRNT80 &lt; 1:40 booster series . 4 . If female childbearing potential , must agree urine pregnancy test day vaccine . ( Exception : documented hysterectomy â‰¥ 3 year menopause . ) The result must negative . Females must agree become pregnant 3 month receipt last study treatment ( vaccination ) . 5 . Be consider risk exposure EEE virus submit Request IND Vaccines EEE vaccine . 6 . Sign date approve informed consent document HIPAA Authorization . 7 . Have chart : medical history ( include concomitant medication ) within 60 day plan first administration vaccine physical examination laboratory test within 1 year previous chest radiograph result electrocardiogram 8 . Be medically clear participation investigator . ( Examinations and/or test may repeat discretion principal investigator [ PI ] . ) 9 . Be willing return followup visit . 10 . Agree report adverse event ( AEs ) may may associate administration vaccine least 28 day administration agree report serious adverse event ( example , result hospitalization ) duration subject 's participation study . Subjects must agree report pregnancy occur within 3 month vaccination . 11 . Agree defer blood , bone marrow , organ donation 1 year receipt vaccine . 1 . Have complete previous EEE vaccine study nonresponder . 2 . Have clinically significant abnormal laboratory result ( include evidence hepatitis C , hepatitis B carrier state ) elevate liver function test ( two time normal range discretion PI ) . 3 . Have personal history immunodeficiency receive treatment immunosuppressive medication , systemically administer glucocorticoid ( eg , prednisone ) within 1 month plan administration vaccine immunosuppressive therapy within 6 month plan administration vaccine . Other immunosuppressive therapy include cancer chemotherapeutic agent , drug prevent transplant rejection , interferon , monoclonal antibody , protein kinase inhibitor , methotrexate , TNF ( tumor necrosis factor ) inhibitor , drug determine immunosuppressive PI . Current administration topical , inhalational , intranasal glucocorticoid exclude . 4 . Have confirm HIV infection ( antibody positivity ) . 5 . Have positive pregnancy test breastfeed female . 6 . Have know allergy component vaccine : Neomycin sulfate Formaldehyde Egg Human serum albumin Sodium bisulfite 7 . Have administration another vaccine investigational product within 28 day EEE vaccination . 8 . Have unresolved AE result previous immunization . 9 . Have medical condition , judgment PI , would impact subject safety .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>